Section 01
What Tesofensine Actually Is
⚠️The Classification Most Vendors Get Wrong
Dozens of vendor sites, medspa landing pages, and research chemical suppliers list tesofensine as a "weight loss peptide." This is factually incorrect. Tesofensine has no amino acid chains, no peptide bonds, and no mechanism resembling GLP-1 agonists or growth hormone secretagogues. Its mechanism is closer to Contrave, Cymbalta, or tricyclic antidepressants. We mention this not to be pedantic, but because the misclassification creates false expectations about how the compound works and who should not take it.
Tesofensine is not a peptide. It is a small-molecule triple monoamine reuptake inhibitor from the phenyltropane chemical family. Chemically, it is closer to an antidepressant than to any peptide used in weight management.
Its origin is surprising. Originally developed by Danish firm NeuroSearch for Parkinson's disease and Alzheimer's disease, tesofensine failed both indications. Weight loss was a consistent side effect in overweight trial participants, which became the compound's entire new purpose.
220 hrs
Half-life: blood levels peak 5–8 hours and persist for days. Slow kinetics reduce abuse potential.
9.2%
Mean body weight loss at 0.5 mg over 24 weeks in Phase IIb TIPO-1 trial (Astrup et al., The Lancet, 2008)
Phase IIb
Highest completed trial stage. No Phase III data. No FDA NDA filed. No post-marketing safety surveillance.
"It's Like Cocaine, But No Fun."
— Discover Magazine, reporting on Schoedel 2010 trial findings. Slow kinetics eliminate abuse potential despite the dopaminergic mechanism
Section 02
Who It's Actually For
| Patient Profile | Fit | Why |
|---|---|---|
| GLP-1 Non-Responder | Strong Fit | 18.6% of GLP-1 patients are primary non-responders. Tesofensine works through an entirely different mechanism, blocking monoamine reuptake rather than mimicking a gut hormone. A different mechanism may produce results where GLP-1s failed. |
| GLP-1 Dropout Due to GI Intolerance | Strong Fit | Tesofensine's side effects are stimulant-adjacent (dry mouth, insomnia, mild heart rate increase) rather than GI-centric. Patients who cannot tolerate GLP-1 gut effects often tolerate tesofensine well. |
| Body Composition Optimizer | Conditional Fit | Oral, rapid appetite suppression within days, long half-life providing stable once-daily dosing. Requires cardiovascular monitoring and physician supervision throughout. |
| Cognitive Biohacker | Conditional Fit | Elevated synaptic dopamine and norepinephrine improve executive function and motivation. Weight loss is real. However, patients with anxiety disorders should not use this compound; stimulant-like side effects will exacerbate anxiety. |
CV Risk / Psychiatric History Uncontrolled hypertension, arrhythmia, bipolar, untreated anxiety, SSRI/MAOI use | Contraindicated | Tesofensine raises resting HR by 7.4 bpm at therapeutic doses. 56.2% of trial subjects had peak HR increase of 10+ bpm. 6.1% on 1 mg reported depressed mood vs. 0% placebo. Combining with MAOIs or SSRIs risks serotonin syndrome, which can be fatal. |
Patient Profile
Fit
Why
Patient Profile
Fit
Why
Patient Profile
Fit
Why
Patient Profile
Fit
Why
Patient Profile
Uncontrolled hypertension, arrhythmia, bipolar, untreated anxiety, SSRI/MAOI use
Fit
Why
🔬The GLP-1 Non-Responder Data
Approximately 18.6% of patients do not respond to GLP-1 receptor agonists. This non-response is likely genetic and metabolic, not a failure of willpower or adherence. Tesofensine's mechanism (monoamine reuptake inhibition) is entirely distinct from GLP-1 mimicry. For patients in this 18.6%, a different mechanism represents a genuine clinical option, not a consolation prize.
"Pumped for this. My fat ass needs all the help it can get when it comes to hunger."
— Steroidology forum, early community discussion of tesofensine's Phase II results
Section 03
How It Works
⚠️Not a Hormone. Not a Peptide. Not a Metabolic Shortcut.
Tesofensine does not repair the metabolic dysfunction that caused weight gain. It does not improve insulin sensitivity, GLP-1 secretion, or leptin signaling. It suppresses appetite and may increase resting energy expenditure. When you stop taking it, appetite returns to baseline. There is no evidence of permanent metabolic improvement from tesofensine use.
Appetite Suppression (Serotonin)
Tesofensine blocks serotonin reuptake, increasing synaptic serotonin in hypothalamic feeding centers. This produces a sustained reduction in hunger signaling that most patients describe as "not thinking about food." The effect is mechanistically similar to how SSRIs cause appetite changes, but tesofensine's triple-reuptake profile produces a more pronounced and consistent appetite effect.
Energy Expenditure (Norepinephrine)
Norepinephrine reuptake inhibition increases sympathetic nervous system tone, modestly raising resting metabolic rate. This is the same mechanism that makes phentermine thermogenic. The Phase IIb data suggest a small increase in resting energy expenditure, though the majority of weight loss comes from reduced caloric intake, not increased burn.
Motivation and Reward (Dopamine)
Dopamine reuptake inhibition reduces the hedonic drive to eat. Food is less rewarding. This is not the same as not being hungry. It means the psychological pull toward high-calorie food diminishes. Patients describe eating as "functional" rather than "pleasurable." This dopaminergic effect also produces the mild cognitive enhancement some users report.
A 2024 PLOS One study confirmed that tesofensine silences GABAergic neurons in the lateral hypothalamus, a brain region governing feeding behavior. This hypothalamic mechanism operates downstream of the triple reuptake inhibition and may explain why appetite suppression is more consistent with tesofensine than with single-reuptake inhibitors.
🔬Why the Long Half-Life Matters Clinically
Tesofensine has a half-life of approximately 220 hours, nearly 9 days. Blood levels rise slowly over 5 to 8 hours after each dose and remain stable between doses. This contrasts sharply with amphetamines, which reach peak blood levels within 1 to 3 hours and fall equally fast. The slow kinetics produce steady appetite suppression without the "crash" associated with short-acting stimulants. They also mean that if side effects develop, they persist for days after stopping the drug. This is not a compound to experiment with impulsively.
"Users often feel satiated sooner while eating and felt satiated longer after eating, reducing overall caloric intake naturally."
— Bodybuilding community post on tesofensine mechanism
Section 04
Realistic Expectations
Appetite Begins Shifting
Most patients report meaningful appetite suppression within 72 hours of the first dose. This is faster than GLP-1 agents, which typically require 2 to 4 weeks for full appetite effect. Dry mouth and mild insomnia may begin here. Take the dose fasted, in the morning. Do not take after noon.
Titration Period
VitalRx protocols begin at 0.25 mg to assess individual cardiovascular and CNS tolerance. Blood pressure and resting heart rate are monitored. Dose escalation to 0.5 mg occurs only if titration is well tolerated. Some patients remain at 0.25 mg throughout.
Measurable Weight Change
With caloric adherence, weight loss becomes measurable. Phase IIb data show approximately 4.5% body weight loss at 0.25 mg and 9.2% at 0.5 mg over the full 24-week trial. Expect 1 to 2 lbs per week on average. Results vary by individual, dose, and dietary adherence.
Standard Cycle Endpoint
VitalRx protocols use an 8 to 12 week active cycle. Some patients continue to 24 weeks (matching the Phase IIb trial duration). Tolerance development at higher doses has been reported anecdotally; physician review of continued dosing is required at the cycle endpoint.
Washout and Re-evaluation
A 4-week washout period is standard before any subsequent cycle. Appetite returns to pre-treatment baseline during washout. Weight regain is possible without caloric discipline. Tesofensine produces no permanent appetite suppression. This is expected, not a failure.
⚠️Non-Responder Rate: Not Yet Quantified in Large Trials
Tesofensine has not completed Phase III trials. Non-responder rates are not established at the population level. The Phase IIb trial reported results across a cohort of 203 patients, but individual variation was significant. Some patients lose 6 to 8% on 0.5 mg. Others lose 14%. A small number may lose less than 3%. There is no pre-treatment biomarker that predicts response. This is a clinical reality, not a marketing problem, and it is why physician oversight and honest reassessment are required.
⚠️When You Stop: What the Evidence Says
Tesofensine is not a cure for obesity. When the drug is discontinued, monoamine reuptake returns to baseline, appetite suppression ends, and the central nervous system adapts back to its prior state. The long half-life (220 hours) means withdrawal is gradual rather than abrupt. Most patients do not experience a crash. However, patients who relied entirely on tesofensine for appetite control without building dietary habits during the protocol frequently regain weight. The drug works best as a tool within a structured behavioral program, not as a standalone intervention.
Section 05
Dosing Protocol
Tesofensine is taken orally, once daily, as a capsule. It is not injectable. Take it fasted, in the morning, ideally 30 to 60 minutes before eating. Taking it later in the day significantly increases the likelihood of insomnia, given the stimulant-adjacent mechanism and long half-life. Do not split doses.
| Protocol | Daily Dose | Evidence Basis | Notes |
|---|---|---|---|
| Phase IIb Trial (Clinical Reference) | 0.5 mg once daily (titration from 0.25 mg) | TIPO-1 trial, The Lancet 2008. 203 patients, 24 weeks | Clinical standard. 9.2% mean weight loss. HR increase of 7.4 bpm. |
| VitalRx Protocol (Standard) | 0.25 mg daily for weeks 1–2, then 0.5 mg daily as tolerated | Based on TIPO-1 titration design with additional cardiovascular safety margin | Physician-Supervised BP and resting HR documented at each check-in. Dose held at 0.25 mg if CV parameters exceed thresholds. |
| VitalRx Protocol (Conservative) | 0.25 mg daily throughout cycle. No escalation. | Clinical judgment; lower end of TIPO-1 efficacy (4.5% mean weight loss) | Physician-Determined For borderline hypertension or elevated resting HR at baseline. |
| Gray Market / Self-Directed | 0.5 mg–1.0 mg, variable titration | Community anecdote, no controlled data | Not Recommended Purity unverified. No CV monitoring. Multiple reports of zero-effect products. |
Protocol
Daily Dose
Evidence Basis
Notes
Protocol
Daily Dose
Evidence Basis
Notes
Protocol
Daily Dose
Evidence Basis
Notes
Protocol
Daily Dose
Evidence Basis
Notes
✦Why Physician Supervision Is Clinically Necessary Here
Tesofensine's cardiovascular signal is real. In the TIPO-1 trial, 56.2% of patients on active tesofensine had a peak heart rate increase of 10 or more beats per minute, compared to 18.8% on placebo. 5.7% of tesofensine subjects had a sustained systolic blood pressure elevation. These are not theoretical risks. VitalRx requires a baseline ECG, blood pressure documentation, and resting heart rate before dispensing. Heart rate and blood pressure are reviewed at each 28-day check-in. Patients whose HR or BP exceeds threshold are dose-reduced or discontinued. No gray market vendor does this. No unsupervised self-dosing protocol can do this.
"The abuse potential for tesofensine is no greater than that of bupropion or atomoxetine, and tesofensine is therefore unlikely to be recreationally abused."
— Schoedel et al., Clinical Pharmacology & Therapeutics, 2010
Section 06
Cycling: Evidence vs. Myth
⚠️What the Evidence Actually Says About Cycling
There is no controlled clinical data on optimal cycling protocols for tesofensine. The Phase IIb trial ran continuously for 24 weeks without a break. The TIPO-4 extension ran for 48 weeks continuously. Community protocols recommending 5-days-on/2-days-off or 8-week cycles with 4-week washouts are based on bodybuilding community convention and anecdote, not published pharmacokinetic research. VitalRx protocols are 8 to 12 weeks with physician review at endpoint, based on the available trial design, not community mythology.
| Community Claim | Evidence Status |
|---|---|
| "5-days-on/2-days-off prevents tolerance" | No Evidence Anecdotal community convention. The 220-hour half-life makes short on/off windows clinically questionable. |
| "8–12 week cycles match the research" | Partially Supported Clinical trials ran 24 and 48 weeks continuously. 8–12 weeks is shorter than the trial design. |
| "You must cycle off to avoid tolerance" | Plausible but Unproven Clinical trial showed continued efficacy at 48 weeks without cycling. Individual variation is significant. |
| "A 4-week washout resets everything" | No Evidence 220-hour half-life means tesofensine is not fully cleared in 4 weeks. Some pharmacological effect persists. |
| "Higher doses break through tolerance" | Not Recommended The 1 mg dose produces more psychiatric and cardiovascular adverse events. Dose escalation to overcome tolerance is not physician-approved. |
Community Claim
Evidence Status
Community Claim
Evidence Status
Community Claim
Evidence Status
Community Claim
Evidence Status
Community Claim
Evidence Status
VitalRx does not prescribe cycling schedules from the internet. Each cycle endpoint is a physician review, not a calendar event. Continuation, dose adjustment, or pause depends on cardiovascular parameters, body composition progress, patient-reported side effects, and lab findings. This is not a product to run by feel.
Section 07
Physician-Sourced. Cold-Chain Shipped.
✦Pre-Constituted. Cold-Chain Shipped. Physician-Labeled.
VitalRx tesofensine is compounded at a 503B-registered facility and shipped in temperature-controlled packaging directly to the patient. Every shipment includes the prescribing physician's name, the patient name, dose, and dispense date — because it is a compounded medication, not a research chemical. The compound arrives labeled, dosed, and ready to use. No reconstitution. No guesswork. No purchasing from a vendor whose quality assurance is a forum post.
503B
Registered outsourcing facility: highest tier of manufacturing oversight for compounded medications
0
Reconstitution steps required. Arrives as an oral capsule, physician-compounded and labeled
COA
Certificate of Analysis accompanies every batch: third-party verified potency, purity, and sterility
Each monthly shipment contains: capsule medication in a labeled, sealed container; dispensing information with dosing instructions; and a patient card with emergency contact and prescribing physician information. Store at room temperature, away from heat and humidity. Medication should be kept out of direct sunlight.
⚡The Quality Problem the Gray Market Created
Community forums document a consistent pattern: patient purchases tesofensine from an unverified online vendor, experiences zero appetite suppression or results, assumes the compound doesn't work, gives up. Later, the same patient tries a physician-compounded source and experiences dramatic appetite suppression within 72 hours. The compound didn't change. The purity did. Tesofensine purchased from research chemical sites has no guaranteed potency, no sterility testing, and no dosing verification. The failure isn't the molecule. It's the product.
"Absolutely NOT hungry and has eaten a small amount of polenta in 24 hours."
— TheIronDen forum, 2025 — user describing his wife's experience after restarting tesofensine from a verified formulation following GLP-1 failure
Section 08
Lab Monitoring Requirements
Tesofensine is not a compound where lab monitoring is optional. The Phase IIb TIPO-1 trial documented a mean 7.4 bpm heart rate increase and 1.5 mmHg diastolic blood pressure increase at the therapeutic 0.5 mg dose. 56.2% of active-treatment subjects had a peak heart rate increase of 10 or more beats per minute. VitalRx requires the following panel before dispensing and at 28-day intervals throughout the protocol.
Cardiovascular Baseline
Resting Heart Rate + Blood Pressure
HR under 85 bpm | BP under 130/85 mmHg
Tesofensine raises both. Patients above thresholds at baseline require physician review before dispensing. Documented at every check-in.
Liver Function
ALT, AST, ALP, Total Bilirubin
ALT/AST under 40 U/L | ALP under 120 U/L
Long half-life means hepatic clearance is ongoing throughout a cycle. Liver enzyme monitoring detects early hepatotoxicity signals.
Metabolic Panel
Fasting Glucose + HbA1c
Fasting glucose under 100 mg/dL | HbA1c under 5.7%
Many candidates have metabolic syndrome or prediabetes. Baseline glucose establishes risk profile.
Lipid Panel
LDL, HDL, Triglycerides, Total Cholesterol
LDL under 130 mg/dL | TG under 150 mg/dL
Weight loss generally improves lipid profiles. Monitoring confirms expected improvement and screens for adverse signals.
Thyroid Function
TSH (Thyroid Stimulating Hormone)
TSH: 0.4 – 4.0 mIU/L
Hyperthyroidism and tesofensine share overlapping CV effects. TSH rules out additive risk at baseline.
Complete Blood Count
CBC with Differential
Standard reference ranges
Baseline CBC establishes normal hematological function. Any unexpected signal is identified before protocol begins.
✦Why We Require Labs Every 28 Days
Most online tesofensine sources include no monitoring at all. VitalRx requires a 6-marker lab panel before dispensing and at 28-day intervals throughout the protocol. This is not bureaucratic friction. It is the clinical standard that makes physician supervision meaningful. A patient whose resting heart rate climbs from 72 to 91 bpm during a tesofensine protocol needs a dose adjustment, not another 30-day supply. Our physician review catches this. No gray market vendor does.
Section 09
Stacking
Tesofensine stacks reasonably with a handful of compounds that address complementary mechanisms. It does not stack well with anything that shares its cardiovascular or serotonergic burden. The following table reflects mechanism-based rationale from the clinical and community literature, not marketing claims.
| Compound | Class | Why It Pairs | VitalRx Availability |
|---|---|---|---|
| AOD-9604 | Peptide (GH fragment 176–191) | Fat-specific lipolysis without appetite or metabolic effects. Complementary, non-overlapping mechanisms. No CV or serotonergic interaction. | Available |
| BPC-157 | Peptide (body protection compound) | Caloric restriction increases soft tissue stress. BPC-157 accelerates tendon, ligament, and gut healing. No pharmacological interaction with tesofensine. | Available |
| Omega-3 / Krill Oil | Supplement | Modestly reduce triglycerides with mild anti-inflammatory CV effects. Reasonable support supplement alongside CV monitoring. | OTC, Patient-Sourced |
| DHEA | Hormone precursor | Caloric restriction reduces DHEA and can suppress hormonal function. Supports adrenal and sex hormone baseline. No direct interaction. | OTC, Physician Discussion |
Compound
Class
Why It Pairs
VitalRx Availability
Compound
Class
Why It Pairs
VitalRx Availability
Compound
Class
Why It Pairs
VitalRx Availability
Compound
Class
Why It Pairs
VitalRx Availability
🚫What NOT to Stack With Tesofensine: Hard Stops
MAOIs: Combining any monoamine reuptake inhibitor with MAOIs creates acute serotonin syndrome risk. This is potentially fatal. Absolute contraindication. A 14-day washout of MAOIs is required before starting tesofensine.
SSRIs and SNRIs: Adding tesofensine to existing SSRI or SNRI therapy creates additive serotonergic and noradrenergic effects. Risk of serotonin toxicity and exaggerated cardiovascular response. Not recommended without specialist psychiatric review.
Phentermine and amphetamines: Additive cardiovascular burden. Combined stimulant and norepinephrine effects create unacceptable hypertension and tachycardia risk. Absolute contraindication.
Yohimbine: Alpha-2 adrenergic antagonist. Directly opposes one of norepinephrine's regulatory mechanisms, creating additive cardiovascular stimulation. Avoid.
GLP-1 agonists concurrently: No direct pharmacological interaction, but dual-therapy weight loss protocols require specialist oversight and are not a standard VitalRx protocol.
Section 10
Pricing
⚠️The Number Most Vendors Hide
Tesofensine pricing at medspas and telehealth clinics is routinely presented as a per-month medication cost, without disclosing that the required labs, physician consultation, and ongoing monitoring are billed separately, sometimes adding $150 to $300 to the first-month cost. VitalRx pricing is all-in. What you see is what you pay. No hidden lab bills. No separate consultation fees layered on top.
| Option | Monthly Cost | Labs / Oversight | Quality |
|---|---|---|---|
| Semaglutide / Wegovy (Reference) | ~$1,350/mo brand | ~$300–$500/mo compounded | Labs not standard. Oversight varies. | FDA-approved brand | variable compounded |
| Other Medical Clinics | From $200 advertised. Labs, consult fees not publicly disclosed. | Not publicly disclosed | Verify Before Committing |
| Gray Market / Research Chemical | ~$80–$150/month | None | Unverified Multiple reports of zero-effect products. No COA. |
| VitalRx, Month 1 (Titration) | Pricing confirmed at consult | Labs + Physician Included | 503B Registered — COA Available |
| VitalRx, Month 2+ | Pricing confirmed at consult | Monthly Monitoring Included | 503B Registered |
Option
Monthly Cost
Labs / Oversight
Quality
Option
Monthly Cost
Labs / Oversight
Quality
Option
Monthly Cost
Labs / Oversight
Quality
Option
Monthly Cost
Labs / Oversight
Quality
Option
Monthly Cost
Labs / Oversight
Quality
Semaglutide (Reference)
~$300–$1,350/mo
FDA-approved. Insurance-coverable. 14.9% weight loss at 68 weeks.
ReferenceOther Clinics
From $200
Labs, consult fees not publicly disclosed.
VerifyGray Market
~$80–$150/mo
No labs. No oversight. Purity unverified.
UnregulatedVitalRx, All-In
Confirmed at consult
503B compounded, 6-marker labs, physician oversight, cold-chain shipping.
All-InPrice Breakdown
Medication
Compounded Tesofensine
0.25–0.5 mg daily capsule
28–30 day supply, physician-labeled, cold-chain shipped from 503B registered facility.
Physician Oversight
Initial consultation + monthly review
Licensed in your state
Intake assessment, cardiovascular screening, protocol design, and 28-day check-in included. Not billed separately.
6-Marker Panel
HR, BP, liver, CBC, glucose, lipids, TSH
Baseline + monthly
Required at intake and every 28 days. Included in pricing. Results reviewed by physician before each refill.
Delivery
Cold-chain, insured shipping
All 50 states
Physician-labeled, temperature-controlled packaging. Included. No separate shipping fee.
✦Why Month 1 Is Different
The first month of a tesofensine protocol is a titration period, starting at 0.25 mg while cardiovascular tolerance is assessed. More physician contact happens in Month 1 than in subsequent months. The dosing is lower. The check-in cadence is higher. At VitalRx, Month 1 pricing reflects the intake consultation, baseline labs, and initial supply. Month 2+ reflects the ongoing monitoring and medication. All-in. No billing surprises.
Section 11
Legal Access in All 50 States
Not FDA-Approved
No NDA filed. Phase IIb completed. Phase III ongoing.
Compounding Legal
Available via physician prescription through 503B pharmacies in all 50 states
Not a Scheduled Substance
Abuse potential no greater than bupropion (Schoedel 2010)
WADA Status: Check
Athletes should confirm current prohibited list status before starting
The Three-Layer Regulatory Picture
Layer 1: FDA Status. Tesofensine has not received FDA approval for any indication in the United States. Phase IIb trials were completed successfully in 2008 (TIPO-1, The Lancet). Phase III trials have been ongoing under various development programs, including NeuroSearch and later Saniona, but no New Drug Application has been filed as of early 2026. The compound is approved for obesity treatment in Mexico under certain regulatory frameworks. In the US, it is available only through the compounding pathway.
Layer 2: 503B Compounding Access. Tesofensine is not listed on the FDA's Category 2 bulk drug substances list. It is not a peptide and was not affected by the 2024 to 2025 reclassification discussions that targeted compounded peptides. As of March 2026, tesofensine can be legally compounded at 503B-registered outsourcing facilities under physician prescription. This regulatory status may change. VitalRx monitors the FDA regulatory environment and will notify patients of any changes.
Layer 3: Scheduling and Controlled Status. Tesofensine is not a DEA-scheduled controlled substance. The clinical abuse potential study (Schoedel et al., 2010) found abuse potential no greater than bupropion. The slow oral kinetics (peak blood levels at 5 to 8 hours, half-life of 220 hours) produce no acute euphoria or reward response. Recreational stimulant users in the crossover study described tesofensine at 1 mg (twice therapeutic dose) as producing effects essentially indistinguishable from placebo.
✦Legal Prescription Access — How VitalRx Does It
Every tesofensine protocol dispensed through VitalRx involves a licensed physician in the patient's state reviewing intake questionnaire responses, medical history, and cardiovascular screening data. The physician determines clinical appropriateness and issues a prescription. The prescription is filled by our 503B-registered compounding pharmacy and shipped directly to the patient. This is the legal, supervised pathway, not a research chemical purchase or a gray market transaction.
⚡One Legal Claim We Cannot Make Categorically
We have reviewed the current regulatory landscape to the best of our knowledge as of March 2026. Regulatory status for compounded medications can change with FDA guidance, scheduling decisions, or enforcement actions. VitalRx's legal compliance team reviews this status continuously. We do not guarantee that any specific access claim remains accurate indefinitely, and we will communicate any changes to active patients proactively.
"Without FDA approval, you're basically trusting your compounder, your prescriber, and a Phase II trial from 2008. That's a lot of trust."
— Weight loss forum skeptic, community discussion of tesofensine's evidence base
Section 12
Community Q&A
These are questions the weight loss and biohacking communities actually ask about tesofensine. The answers are based on clinical data where it exists, and honest disclosure where it doesn't.
Section 13
The VitalRx Model
This guide disclosed a cardiovascular signal, a non-response rate that hasn't been quantified, a psychiatric adverse event at higher doses, a product quality failure in the gray market, and the absence of Phase III data. If that level of transparency is unusual for a weight loss clinic, that's because most weight loss clinics are selling something. VitalRx is not selling tesofensine. VitalRx is offering physician-supervised access to it, with the monitoring, sourcing, and clinical oversight that make the risk-benefit calculation actually calculable.
503B Registered Sourcing
Every compound dispensed through VitalRx is manufactured at a 503B-registered outsourcing facility. This is the FDA's highest tier of manufacturing oversight for compounded medications. Certificate of Analysis available on request.
Physician-Supervised CV Monitoring
Tesofensine's heart rate elevation is real and requires oversight. Every patient has a documented baseline cardiovascular profile before the first dose and a 28-day review before each refill. A physician, not an algorithm, reviews your parameters.
Labs Included, No Surprises
The 6-marker monitoring panel is included in your monthly fee. No separate lab bill. No surprise charge from a third-party draw center. Your results go directly to your prescribing physician before each refill is authorized.
Legal Access, 50 States
VitalRx operates through licensed physicians in every state. Your prescription is issued by a physician licensed in your state, filled by a 503B-registered compounding pharmacy, and shipped legally to your address. No gray market. No research chemical purchase.